PDS Biotechnology CorporationPDSB
Key ratios
ROA
-52.0%2025
2024
-43.3%2023
-39.5%
ROE
-244.2%2025
2024
-166.7%2023
-122.5%
Recent news
PDS Biotechnology Appoints Three Accomplished Pharma Industry Executives to Board of Directors
PDS Biotech to Host Key Opinion Leader Event on PDS0301 for the Treatment of Advanced Colorectal Cancer with Liver Metastases
PDS Biotech Announces Publication of VERSATILE-002 Phase 2 Results in JAMA Oncology
PDS Biotech Announces Initial Closing of up to $22.3 Million PIPE Financing and the Appointment of Dr. Patrick Soon-Shiong to Its Board of Directors
PDS Biotech Reports Second Quarter 2026 Financial Results
PDS Biotech Announces Strategic Refocus Prioritizing PDS0301 in Metastatic Colorectal Cancer (mCRC) and Partnership Strategy for PDS0101
Track PDSB in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer